吡格列酮对2型糖尿病患者血浆纤溶酶原激活物抑制剂-1的影响

目的:探讨吡格列酮对2型糖尿病(T2DM)患者血浆纤溶酶原激活物抑制剂-1(PAI-1)的影响。方法:70名T2DM患者,随机双盲分为安慰剂组(A组,35例)和吡格列酮组(B组,35例),治疗3个月后,检测两组患者服药前后空腹血糖(FBG)、空腹胰岛素(FINS)、糖基化血红蛋白(HbA1c)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂-1(PAI-1),并计算胰岛素敏感指数(ISI)。结果:治疗后吡格列酮组FBG、FINS、HbA1c、TG、PAI-1明显下降(P<0.01),HDL-C、ISI显著升高(P<0.01),t-PA无明显变化,且PAI-1与FINS、TG呈正相关(r=0.437,r=0.342,P<0.05),与ISI呈负相关(r=-0.552,P<0.01);安慰剂组各参数于治疗前后无显著性差异。结论:吡格列酮能够显著降低T2DM患者的PAI-1。

Effect of Pioglitazone on Plasminogen Activator Inhibitor-1 of Plasma in Type 2 Diabetic Mellitus Patients

Objective: To study the effect of pioglitazone on plasminogen activator inhibitor1(PAI1) of plasma in type 2 diabetic mellitus (T2DM) patients. Methods: T2DM patients (n=70) were divided into the placebo g roup (n=35) and pioglitazone group (n=35) by the rule of random and doub leblind. Before treatment and 3 months later, fasting blood glucose (FBG), fas ting insulin (FINS), HbA_1c, triglyceride(TG), high density lipoproteinchol esterol(HDLC), tissueplasminogen activator(tPA) and PAI1 were measured . The insulin sensibility index (ISI) was calculated. Results: In the pioglitazone group, the levels of FBG, FINS, HbA_1c, TG and PAI1 were significantly decreased and the values of ISI and HDLC were markedly increase d(P<0.01)after treatment. The API value had positive correlation to FINS a nd TG(r=0.437 and r=0.342, respectively, each P<0.05), and had n egative correlation to ISI (r=-0.552,P<0.01). In the placebo group, there were no significant differences in the levels of FBG, FINS, HbA_1c, ISI, TG, HDLC, tPA and PAI1 before and after treatment. Conclusion: Pioglitazone could significantly reduce PAI1 in T2DM patients.